Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carelwon
- Development stage
- Unknown
- Lead developer
- Evithé Biotechnology
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Carelwon is a patented, bioactivated ginger rhizome botanical tincture developed by Evithé Biotechnology. It is standardized to deliver 50 mg of zingerone, a stable phenolic compound, per 4 ml dose. The drug is designed to simultaneously address six inflammatory pathways and is primarily being developed for the treatment of chronic inflammatory diseases such as rheumatoid arthritis, with additional potential in Alzheimer's disease and sepsis. Evithé Biotechnology has completed a first-in-human Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of oral Carelwon in healthy adult volunteers.
- Brand names
- Carelwon
- Other names
- zingeroneginger rhizome botanical tincture
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on Carelwon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carelwon.